STAT+: Centene agrees to pay $28 million to resolve another state probe into its PBM business
Centene (CNC), one of the largest health insurers in the U.S., agreed to pay nearly…
Category: Pharma
STAT+: Pharmalittle: Glaxo and Vir antibody remains effective against Omicron; Biden talks up drug-pricing reform
Top of the morning to you, and a fine one it is. Sunny skies and…
.jpg)
STAT+: Targeting prices for accelerated approval drugs may have limited impact on overall drug spending
As U.S. regulators approve more medicines under the accelerated approval pathway, Medicare and Medicaid continue…
STAT+: An advocacy group seeks to broaden access to a Pfizer Covid-19 pill
In a bid to expand access to the Pfizer (PFE) Covid-19 pill, an advocacy group…
STAT+: Pharmalittle: Covid-19 pills may take longer to reach poor countries; J&J Covid booster may be as beneficial as a third Pfizer shot
Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing…
STAT+: Pharmalittle: FDA plans rapid review of Omicron vaccines and drugs; Califf would keep Woodcock at FDA
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Former Immunomedics executives are charged with insider trading
Two former executives at Immuomedics were charged with insider trading by U.S. authorities in connection…
STAT+: Pharmalittle: Glaxo and Vir drug appears to work against Omicron; employees sue Bristol Myers over vaccine mandate
Rise and shine, another busy day is on the way. However, this is also shaping…
.jpg)
STAT+: Amgen joins a growing list of drug makers cutting discounts to safety-net hospitals
Amid a closely watched legal battle, Amgen (AMGN) has joined the growing ranks of major…
STAT+: Pharmalittle: Merck Covid pill squeaks past FDA panel; analysis explores whether insurers give ‘fair access’ to drugs
Top of the morning to you, and a fine one it is. A shiny sun…
STAT+: Just how many barriers do health insurers create to fair access to medicines?
Do large health insurers in the U.S. provide “fair access” to prescription medicines? The answer…
STAT+: Socially responsible investor coalitions push greater access to medicines in shareholder proposals
Amid controversy over equitable distribution of Covid-19 vaccines, a large coalition of socially minded investor…
States: Sackler family members abusing bankruptcy process
NEW YORK — A federal judge should reject a sweeping settlement to thousands of lawsuits…
STAT+: Pharmalittle: Moderna CEO cautions Covid shots will be less effective against Omicron; Pfizer predicts new vaccine for the variant in 100 days
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: McDonald’s accused of dragging its feet on goal of reducing antibiotic use in beef supplies
Dozens of advocacy groups are accusing McDonald’s (MCD) of failing to follow through on creating…
The Omicron variant underscores the global stakes of Covid-19 vaccine inequity
The sudden emergence of the Omicron variant of SARS-CoV-2 is adding pressure on vaccine makers…
STAT+: Pharmalittle: Vaccine makers scramble to assess the Omicron Covid strain; Pfizer to step up Covid pill production
Good morning, everyone, and welcome to another working week. We hope the extended weekend break…
STAT+: Pfizer sues former employee for allegedly stealing Covid-19 vaccine documents
Amid the intense race to develop Covid-19 products, Pfizer (PFE) accused a former employee of…
STAT+: Pharmalittle: Jury finds pharmacy chains recklessly distributed opioids; FDA choice Califf has millions invested in pharma
Hello there, and happy pre-Turkey Day. STAT reporter Andrew Joseph here filling in for Mr….
STAT+: Pharmalittle: Aduhelm study shows brain swelling in one-third of patients; Americans may struggle to access Covid antivirals
Good morning, everyone. Hope you’re powering through this short week before the holiday and aren’t…
STAT+: Pharmalittle: CDC endorses Covid-19 boosters for all adults; investors pressure Novartis to spend cash reserves
Good morning, everyone. Damian Garde here, filling in for Ed Silverman at the start of…
STAT+: Pharmalittle: FDA expands emergency use for Pfizer and Moderna Covid boosters; Biden move to lower drug prices would save U.S. $160 billion
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Can local governments convince the courts that opioid makers and wholesalers caused a public nuisance?
Earlier this week, the state of Washington went to trial relying on a controversial legal…
STAT+: GlaxoSmithKline’s Emma Walmsley predicts a ‘landmark’ 2022 for the company
Next year will be a “landmark” one for GlaxoSmithKline, according to CEO Emma Walmsley —…
STAT+: Proposal to waive intellectual property rights for Covid-19 vaccines and drugs appears unlikely to pass
A controversial proposal for the World Trade Organization to temporarily waive intellectual property rights and…
STAT+: A lack of access: Pharma is failing to ensure new antibiotics will be available to poor countries, analysis finds
Although the pharmaceutical industry is making modest progress in countering resistance to superbugs, drug companies…
STAT+: Pharmalittle: SEC probes Cassava over Alzheimer’s drug results; Teva takes pharma in a new direction with a bond sale
Rise and shine, everyone. Another busy day is on the way. We can tell because…
STAT+: By selling bonds tied to drug access and climate goals, Teva takes pharma in a new direction
In a first-of-its-kind move by a drug maker, Teva Pharmaceuticals (TEVA) recently sold $5 billion…
STAT+: ‘Late is better than never’: Biden plan to boost U.S. production of Covid vaccines gets mixed reviews
Under pressure to widen global access to Covid-19 vaccines, the Biden administration plans to invest…
STAT+: ‘Can’t get much worse:’ What a European rejection of an Alzheimer’s drug would mean for Biogen
In a potentially huge setback for Biogen (BIIB), a European regulatory panel signaled that it…
STAT+: FDA is urged to disqualify a hospital review board and two doctors over clinical trial missteps
The Food and Drug Administration is being urged to disqualify a Minnesota hospital and two…
STAT+: Pharmalittle: European regulators unlikely to approve Biogen Alzheimer’s drug; U.S. to invest billions to expand Covid vaccine production
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: ‘Where’s my prescription?’: California wants to revoke an OptumRx pharmacy license for prescribing lapses
The California Board of Pharmacy is seeking to revoke or suspend a pharmacy license held…
Pfizer to file for emergency authorization for its Covid-19 pill
In an anticipated move, Pfizer (PFE) CEO Albert Bourla said the company plans ask the…
STAT+: Pharmalittle: Biogen R&D chief retiring amid controversy over Alzheimer’s drug; Pfizer strikes deal for generic versions of its Covid pill
Top of the morning to you, and a fine one it is. Crystal clear blue…
STAT+: The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $1.6 billion in 2020
During 2020, drug makers raised prices on seven widely used medicines by substantial amounts without…
STAT+: Like Merck, Pfizer strikes a licensing deal with the Medicines Patent Pool for a Covid-19 pill
Amid considerable anticipation over its Covid-19 pill, Pfizer (PFE) reached a licensing agreement with the…
STAT+: Conflicts of interest exist among editors and authors of widely used psychopharmacology textbooks
Amid ongoing concerns over conflicts of interest that may affect medical practice, a new analysis…
STAT+: Biogen’s pricey Alzheimer’s drug will fuel record premium hikes for Medicare Part B
The high cost of the Alzheimer’s drug from Biogen (BIIB) is a key reason that…
STAT+: Pharmalittle: Califf has lots of unfinished FDA business; FDA’s warnings prompt trial sponsors to report results
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: When FDA rattles its sabre, drug makers and universities start reporting overdue trial results
Over the past eight years, more than 90% of drug makers and universities that received…
STAT+: Pharmalittle: J&J to split into two companies; AstraZeneca will price its Covid-19 vaccine to make it profitable
And so, another working week will soon draw to a close. Not a moment too…
STAT+: ‘A work in progress’: BioNTech’s CEO wants to widen Covid-19 vaccine access on his own terms
Two years ago, Ugur Sahin was an under-the-radar but extremely determined scientist running a company…
STAT+: Pharmalittle: NIH to fight Moderna in court over Covid-19 vaccine patents; ‘puzzling’ results in an Alzheimer’s study
Rise and shine, another busy day is on the way. We can tell because our…
STAT+: ‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment
New clinical trial results may temper early hope for an experimental Genentech treatment that targets…
STAT+: Pharmalittle: Moderna and NIH clash over Covid-19 vaccine patent; Biogen probes Alzheimer’s patient death
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Company that sold overdose antidote to pay $12.7 million to settle charges of fraudulent scheme
Kaleo, a small and controversial company, agreed to pay $12.7 million to resolve allegations that…
STAT+: Obesity journal editor’s extensive company ties raise concerns about conflicts of interest in publishing
Over the past seven years, a top editor at a medical journal devoted to obesity…
STAT+: Oklahoma court overturns $465 million opioid verdict against Johnson & Johnson
The Oklahoma Supreme Court overturned a $465 million judgment against Johnson & Johnson (JNJ) in…
STAT+: Pharmalittle: Pelosi was the real holdout in drug-pricing talks; U.S. to pay $1 billion for more Merck Covid pills
Hello, everyone, and how are you this morning? Despite some tech challenges today, we are…